Novotech has selected Oracle’s Siebel Clinical Trial Management System to support the company’s complete spectrum of clinical drug development and research. Novotech works with biotechnology and pharmaceutical companies to bring new healthcare products to the global market by offering a broad range of compliant clinical services. The company is headquartered in Australia with operations in India, New Zealand, South Korea and across Southeast Asia. The company has helped global customers conduct trials in the Australasian region from first human exposure through to completion of Phase III trials. Novotech has been running a bespoke system to manage their clinical trial operations.
Over time, the business has grown and expanded across the Asia Pacific rim. The existing system did not accommodate the evolving business needs of Novotech as it lacked scalability and flexibility. In order to support the company’s continued growth and an increasingly complex business, Novotech needed a system that was robust and could grow with their operations.
Novotech selected Siebel Clinical Trial Management because it met the organization’s present needs, is a recognized leader and is built on open standards allowing the company to integrate other business applications, such as its financial system. Siebel Clinical Trial Management will also serve as a centralized repository for all investigators to collect and track relevant information about research, including personal profiles to disease specialties. Information will be readily available to manage clinical trials at different tiers–local, regional and global. Siebel Clinical Trial Management will offer a consistent view of the clinical trials undertaken by Novotech and provide up to date information on clinical trial statuses across the organization. Furthermore, Siebel Clinical Trial Management will provide a common platform that will assist Novotech to conduct their activities to achieve operational efficiencies. In addition to managing the end-to-end trial management process, Siebel Clinical Trial Management will assist to provide timely and accurate reports and dashboards to support tactical and strategic decision-making.
Novotech expects to see improved process efficiencies, better trial quality and lower trial costs from the implementation. Plans are underway to integrate Siebel Clinical with Novotech’s finance system. This will help streamline the business and support real time and accurate reporting, enabling traceability and auditability, and helping reduce the risk of errors due to manually entered information.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.